Mostrar el registro sencillo de la publicación

dc.contributor.authorPalomar-Ciria, Nora
dc.contributor.authorMigoya-Borja, Marta
dc.contributor.authorCegla-Schvartzman, Fanny
dc.contributor.authorOvejero, Santiago
dc.contributor.authorAlvarez-Garcia, Raquel
dc.contributor.authorBello, Hugo J.
dc.contributor.authorBaca-Garcia, Enrique
dc.date.accessioned2022-07-05T13:56:53Z
dc.date.available2022-07-05T13:56:53Z
dc.date.issued2021
dc.identifier.urihttp://repositorio.ucm.cl/handle/ucm/3840
dc.description.abstractFifty-one patients suffering an acute episode of schizophrenia and treated with aripiprazole long-acting injectable (ALAI) were chosen to elaborate an observational study in two in-patient units in Spain, in order to examine the effects of early administration during a hospital admission. When treatment with ALAI is administered in the first week of admission (in 31 patients, 60.78%), hospitalization time is significantly reduced, 12.1 days on average. It can be concluded that ALAI is an effective treatment for these patients. Analysis in economic terms and comparison with other LAI antipsychotics are interesting lines for further research.es_CL
dc.language.isoenes_CL
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
dc.sourceInternational Clinical Psychopharmacology, 36(2), 97-100es_CL
dc.titleEarly administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical reportes_CL
dc.typeArticlees_CL
dc.ucm.indexacionScopuses_CL
dc.ucm.indexacionIsies_CL
dc.ucm.urijournals.lww.com/intclinpsychopharm/Abstract/2021/03000/Early_administration_of_aripiprazole_long_acting.5.aspxes_CL
dc.ucm.doidoi.org/10.1097/YIC.0000000000000345es_CL


Ficheros en la publicación

FicherosTamañoFormatoVer

No hay ficheros asociados a esta publicación.

Esta publicación aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo de la publicación

Atribución-NoComercial-SinDerivadas 3.0 Chile
Excepto si se señala otra cosa, la licencia de la publicación se describe como Atribución-NoComercial-SinDerivadas 3.0 Chile